Osteoarthritis Pain Market Competitive Research And Precise Outlook 2023 To 2030

1
Contrive Datum InsightsGlobal Research And
Consulting
A complete solution to explore all the potential
aspect to drive the growth of the business
industries.
Osteoarthritis Pain Market
2
About Us
Contrive Datum Insights (CDI) is a market
intelligence company providing global business
information reports and services. Our exclusive
blend of quantitative forecasting and trends
analysis provides forward-looking insight for
thousands of decision makers. CDIs experienced
team of Analysts, Researchers, and Consultants
uses proprietary data sources and various tools
and techniques to gather, and analyse
information. Our business offerings represent the
latest and the most reliable information
indispensable for businesses to sustain a
competitive edge. Each CDI syndicated research
report covers a different sector such as
chemicals, materials, metals mining,
pharmaceuticals, energy, automotive, food and
beverages, semiconductors, med-devices, consumer
goods and information technology. These reports
provide in-depth analysis and deep segmentation
to possible micro levels. With wider scope and
stratified research methodology, our syndicated
reports strive to serve the overall research
requirement of clients.
3
Services O?ered

• Market Intelligence Market Opportunity
  Assessment
• Market Size Segmentation
• Market Entry Strategy
• Competitor Benchmarking
• Pricing Intelligence
• Customer Intelligence
• Sourcing Intelligence
• New-Generation Products Technologies
• Distribution Sales Channel Assessment

4
Clientele
Some of the global leading clients that we have
served
5
Clientele
Some of the global leading clients that we have
served
6
Market Overview
Rising rates of osteoarthritis, an aging
population, and better education about treatment
alternatives are all contributing to the
expansion of this industry.Pain, stiffness, and
inflammation are hallmark symptoms of
osteoarthritis, a degenerative disease affecting
the joints. Millions of individuals all around
the world suffer with this form of arthritis,
which is by far the most prevalent.
Osteoarthritis affects people of all ages, but it
is more common among the elderly. Osteoarthritis
pain can be treated with a variety of methods,
such as medicine (both over-the-counter and
prescribed), physical therapy, and even
surgery.The report covers the period from 2017 to
2030, with 2022 as the base year, and provides
information in terms of market size, estimations,
and forecasts in terms of sales volume (K units)
and revenue (million USD). The market for
Osteoarthritis Pain treatments worldwide is
broken out in depth in this report. Product,
application, and key player-specific regional
market sizes are also provided. We factored in
the effects of both COVID-19 and the conflict
between Russia and Ukraine when calculating the
potential size of the market.

7
By Region
Some of the most important reasons propelling
this market are the rising elderly population and
the epidemic of obesity. The availability of
sophisticated treatments and the rising incidence
of trauma are also contributing to the expansion
of this market. South America The rising
incidence of chronic conditions including
arthritis and osteoporosis is fueling the
expansion of this industry. The increasing number
of patients dealing with obesity and the aging
population are further factors that will drive
the expansion of this market. The rising rate of
osteoarthritis and the expanding elderly
population in Europe are driving the expansion of
this industry in that continent. More people in
Asia, the Middle East, and Africa are learning
about osteoarthritis and its treatment choices.
This sector is being bolstered by a number of
factors, including an aging population, better
diagnosis and treatment methods, and a more
developed healthcare system. Evolutionary
pressure.
8
The Global Osteoarthritis Pain Market has been
segmented into

• By Application
• Hospital
• Pharmacy
• Other

• By Type
• Oral
• Non-Oral

9
The Global Osteoarthritis Pain Market has been
segmented into

• By Region
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe

• By Region
• North America
• US
• Canada
• Mexico
• Rest of North America
• The Middle East Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

• By Region
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific

10
Market Dynamics
Osteoarthritis pain is commonly treated with
topical, oral, and parenteral medicines. Although
noninvasive approaches to pain management such as
orthopedic braces are used, pain medicines are
widely used due to their low cost and convenience
of usage. Pain medications are commonly used,
including oral analgesics (acetaminophen and
NSAIDs like ibuprofen, naproxen, tramadol,
opiates, and duloxetine), topical agents (like
capsaicin and topical NSAIDs), intra-articular
agents (like corticosteroids and hyaluronic
acid), and nutraceuticals (like glucosamine and
chondroitin). Research shows that these drugs can
reduce chronic pain by as much as 30 percent
after they are administered.The high rate of
adoption of pain drugs for the management of
osteoarthritis pain is likely to continue over
the next decade, which is expected to drive the
expansion of the market during the study
period.Osteoarthritis sufferers frequently turn
to over-the-counter and prescription NSAIDs for
pain relief. More than half of American patients
with osteoarthritis are given NSAIDs, according
to research published in 2019 by the National
Center for Biotechnology Information. Similarly,
in Europe, 60 of the total number of individuals
receiving prescription drugs for osteoarthritis
(47 of the total) received NSAIDs.The concept of
individualized OA drugs is just one example of
the remarkable progress made in the diagnosis,
treatment, and monitoring of disease activity in
patients with OA. To be useful in a tailored
treatment plan for RA, biomarkers must meet a
number of criteria, including their simplicity to
assess, adequate sensitivity and specificity, and
availability and interpretability of testing
procedures. Increased treatment response rates
and less exposure to ineffective or harmful
medications could result from using
11
Market Players

• Abbott Laboratories
• Johnson Johnson
• Novartis International
• Pfizer
• AbbVie
• Abiogen Pharma
• Afferent Pharmaceuticals
• Astellas Pharma
• BioDelivery Sciences International
• Crystal Genomics
• Cytori
• Others.

12
Customer Experiences
13

• By associating with Contrive Datum Insights (CDI)
  , customer can enjoy following benefits
• One-Stop-Destination for all research needs
  (Syndicate and Custom Reports)
• Reduced Budget and Faster Turnaround Time
• Focused Research Team - Contrive Datum Insights
  (CDI) can arrange a dedicated team of 2-3
  resources with 1 Research Manager , who will look
  after any ad-hoc needs of the client
• Dedicated Account Manager
• 24/7 availability for any custom needs of the
  client
• Flexible Partnering Model to accommodate clients
  research needs
• Access to Data-Cuts related to required Market
  for global region
• ? Industry Update on Weekly/Bi-Weekly/Monthly
  basis
• ? Market Trend Analysis on Monthly/Quarterly basis

Benefits of Association
14
Thank You!
To know more about us, please visit our website
www.contrivedatuminsights.com For sales queries
or new topics email us on anna_at_contrivedatuminsig
hts.com